Ensayo clínico fase II, abierto, no controlado y multicéntrico de pazopanib en monoterapia para determinar la eficacia y la seguridad en segunda línea de tratamiento en pacientes con carcinoma de células renales (CCR) avanzado que han progresado o que no han tolerado una primera línea de tratamiento con un inhibidor de la tirosina quinasa (TKI) - Pazopanib

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2011-002441-34-ES

Enrollment

Unknown

Registered

2011-12-07

Start date

2012-01-18

Completion date

Unknown

Last updated

2016-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: Votrient 400 mg comprimidos recubiertos con película Product Name: Votrient Product Code: Votrient Pharmaceutical Form: Tablet INN or Proposed INN: PAZOPANIB HIDROCLORURO Other descriptive

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 14 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 13

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Spain

Contacts

Public ContactMireia Grabulosa

Trial Form Support

mireia.grabulosa@tfscro.com0034931850200270

Outcome results